Siemens performed internal testing which showed a similar bias between calibrator 30 lots ending in 20 and 21.Siemens continues to investigate the issue.The interpretation of results section of the instructions for use states: "results of this assay should always be interpreted in conjunction with patient's medical history, clinical presentation and other findings." advia centaur calibrator 30 kit lots ending in 21.Udi (b)(4).Expiry date march 08 2018.Date of manufacture november 08, 2016.
|
Mdr 1219913-2017-00076 was filed on april 7, 2017 reporting low quality control results for advia centaur xp enhanced estradiol (ee2) when moving to a new lot of calibrator.Low results were observed for patient samples when compared to results obtained with a previous lot of calibrator.Siemens healthcare diagnostics has performed an internal investigation and confirmed a negative bias for advia centaur enhanced estradiol (ee2) on the advia centaur, advia centaur xp and advia centaur xpt systems when calibrating with calibrator 30 kit lots ending in 21 (c3021) as compared to calibrator 30 kit lots ending in 20 (c3020).Siemens' internal investigation has determined that samples with estradiol concentrations of approximately 35 pg/ml (128 pmol/l) and lower exhibit a % bias greater than the expected historical performance of the product when comparing c3021 to c3020.Results observed indicate that as estradiol concentrations increase, the % biases observed become less pronounced.Siemens issued ufsn cc 17-15.A.Ous (june 2017) and umdr cc 17-15.A.Us (june 2017) informing the customer of a negative bias for the advia centaur enhanced estradiol (ee2) on the advia centaur, advia centaur xp and advia centaur xpt systems when calibrating with calibrator 30 kit lots ending in 21 (c3021) as compared to calibrator 30 kit lots ending in 20 (c3020).This issue does not affect the advia centaur cp system.Instructions on actions to be taken are provided in the customer communication.No further investigation is required.
|